A pilot single-arm trial administered 1 mg/day rapamycin for 4 weeks to 23 cognitively normal adults aged 45–65, stratified by APOE4 genotype. Among the nine APOE4 carriers, cerebral blood flow increased by more than 15% across multiple brain regions, while inflammatory cytokine profiles and plasma metabolomics improved concurrently. The fourteen non-carriers showed no significant CBF change, revealing a striking genotype-dependent therapeutic response. Gut microbiome composition also shifted, and adverse effects were minimal at this low dose.
The finding lands at a genuinely productive intersection: APOE4 carriers — roughly 25% of the population and holders of the single largest genetic Alzheimer's risk factor — exhibit cerebrovascular hypoperfusion years before amyloid plaques accumulate, and correcting that deficit early may interrupt a critical upstream driver of neurodegeneration. Rapamycin's mTOR-inhibiting mechanism is already well-characterized as a longevity pathway modulator in animal models, but human cerebrovascular data, especially genotype-stratified data, have been scarce. The 15% CBF gain is clinically meaningful given that even modest perfusion deficits correlate with accelerated cognitive decline in midlife cohorts.
Critical caveats apply heavily here: nine APOE4 carriers is far too small for confident effect-size estimation, there is no placebo arm, and four weeks is insufficient to assess durability or downstream AD biomarker shifts. Still, this is more than incremental — it pilots a precision-medicine framework where rapamycin's utility is genotype-gated, a paradigm that could reshape Alzheimer's prevention trial design if replicated in adequately powered, randomized studies.
